Clinical Trial Update: National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

View source ↗

Summary

EyeGENE Stage 3 expansion to broaden DNA and data repositories for rare inherited ophthalmic diseases; study currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Albinism
• Aniridia
• Best Vitelliform Macular Dystrophy
• Blue-cone Monochromacy
• Corneal Dystrophy
• Hypopigmentation Disorders
• Inherited Retinal Diseases

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Inherited Ophthalmic Diseases, Hypopigmentation Disorder | Status: RECRUITING